Table 5.
Association between CGA results and clinical endpoints.
| Progressive disease and/or decline of IADL-independence (≥2 points) 1 year after chemotherapy | Overall survival | Premature termination of chemotherapy | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | HR | 95% CI | P | OR | 95% CI | P | |
| Age | 1.06 | 1.01-1.12 | .014 | 1.03 | 1.00-1.06 | .087 | 1.05 | 1.01-1.10 | .023 |
| Tumor type and treatment intent | <.001 | <.001 | .059 | ||||||
| Indolent hematological (n = 115) | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| (Neo)adjuvant chemotherapy for solid malignancies (n = 72) | 1.28 | 0.67-2.45 | .451 | 0.84 | 0.52-1.38 | .503 | 1.04 | 0.57-1.92 | .897 |
| Aggressive hematological (n = 55) | 1.04 | 0.52-2.06 | .919 | 1.08 | 0.66-1.78 | .748 | 0.54 | 0.27-1.08 | .081 |
| Palliative chemotherapy for solid malignancies (n = 49) | 5.61 | 2.49-12.64 | <.001 | 2.91 | 1.89-4.48 | <.001 | 1.69 | 0.85-3.34 | .135 |
| Abnormal G8 | 3.60 | 1.98-6.54 | <.001 | 1.71 | 1.16-2.52 | .007 | 2.12 | 1.24-3.65 | .006 |
| CGA | .149 | .352 | .595 | ||||||
| Fit | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref | Ref |
| Vulnerable | 1.55 | 0.72-3.33 | .261 | 1.39 | 0.81-2.39 | .236 | 1.22 | 0.59-2.50 | .593 |
| Frail | 2.14 | 0.98-4.67 | .056 | 1.49 | 0.87-2.57 | .15 | 1.44 | 0.69-3.00 | .326 |
Multivariable logistic regression and Cox proportional hazard models were performed with age and tumor type + treatment intent as independent variables, after which the G8 score and CGA results were added to this model in separate multivariable models.